Table 1.
Clinical characteristics
| Characteristic | Lenvatinib + Nivolumab (n = 40) | Lenvatinib (n = 47) | p value | ||
|---|---|---|---|---|---|
| Age (year, mean ± SD) | 58.5 ± 13.8 | 70.6 ± 13.3 | < 0.01 | ||
| Male | 29 | 72.5.% | 32 | 68.1% | 0.65 |
| Etiologies | |||||
| HBV | 31 | 77.5% | 26 | 55.3% | 0.03 |
| HCV | 4 | 10.0% | 11 | 23.4% | 0.10 |
| Alcohol | 15 | 37.5% | 12 | 26.7% | 0.28 |
| Child–Pugh score class | 0.23 | ||||
| A | 25 | 62.5% | 35 | 74.5% | |
| B | 15 | 37.5% | 12 | 25.5% | |
| ALBI grade | 0.40 | ||||
| Grade 1 | 12 | 30.0% | 18 | 38.3% | |
| Grade 2 | 21 | 52.5% | 25 | 53.2% | |
| Grade 3 | 7 | 17.5% | 4 | 8.5% | |
| BCLC stage | 0.69 | ||||
| B | 17 | 42.5% | 22 | 46.8% | |
| C | 23 | 57.5% | 25 | 53.2% | |
| PVT | 20 | 50.0% | 14 | 29.8% | 0.05 |
| Metastasis | 10 | 25.0% | 17 | 36.2% | 0.26 |
| AFP > 400 (ng/mL) | 10 | 25.0% | 18 | 38.3% | 0.07 |
| Previous drugs | |||||
| Sorafenib | 20 | 50.0% | 0 | 0% | < 0.01 |
| Regorafenib | 2 | 5.0% | 0 | 0% | 0.21 |
| Cabozatinib | 1 | 5.0% | 0 | 0% | 0.46 |
| Line of treatment | < 0.01 | ||||
| 1st line | 17 | 42.5% | 47 | 100% | |
| 2nd line | 16 | 40.0% | 0 | 0% | |
| ≧3rd line | 7 | 17.5% | 0 | 0% | |
| Previous local therapy | |||||
| Surgery | 10 | 25.0% | 15 | 31.9% | 0.48 |
| RFA | 6 | 15.0% | 17 | 36.2% | 0.03 |
| TACE | 23 | 57.5% | 26 | 55.3% | 0.84 |
ALBI grade albumin-bilirubin grade, PVT portal vein thrombosis, AFP alpha- fetoprotein, RFA radiofrequency ablation, TACE transarterial chemoembolization